Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model

Gene Therapy

Volumn 21, Issue 2, 2014, Pages 131-138

  Weber, C ^a   Neacsu, I ^a   Krautz, B ^a   Schlegel, P ^a   Sauer, S ^a   Raake, P ^a   Ritterhoff, J ^a   Jungmann, A ^a   Remppis, A B ^a   Stangassinger, M ^b   Koch, W J ^c   Katus, H A ^a,d   Muller O J ^a   Most, P ^a,c,d   Pleger, S T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

AAV; DNA based therapy; Heart failure; S100A1; Therapeutic window; Translational science

Indexed keywords

ANIMALS; ARRHYTHMIAS, CARDIAC; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; S100 PROTEINS; STROKE VOLUME; SWINE;

EID: 84893735933     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.63     Document Type: Article

References (39)

1. AHA. Heart disease and stroke statistics: 2010 update. Circulation 2010; 21: e1-e170.
2. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 6: 1575-1581.
3. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36: 2072-2080.
4. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med 2010; 362: 228-238.
5. Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.
6. Pleger ST, Boucher M, Most P, Koch WJ. Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. J Card Fail 2007; 13: 401-414.
7. Pleger ST, Brinks H, Ritterhof J, Raake P, Koch WJ, Katus HA et al. Heart failure gene therapy: the path to clinical practice. Circ Res 2013; 113: 792-809.
8. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008; 15: 1550-1557.
9. Lai NC, Roth DM, Gao MH, Tang T, Dalton N, Lai YY et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 2004; 110: 330-336.
10. Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011; 3: 92ra64.
11. Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S et al. AAV6.bARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013; 34: 1437-1447.
12. Kraus C, Rohde D, Weidenhammer C, Qiu G, Pleger ST, Voelkers M et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol 2009; 47: 445-455.
13. Boerries M, Most P, Gledhill JR, Walker JE, Katus HA, Koch WJ et al. Ca2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol 2007; 27: 4365-4373.
14. Gusev K, Ackermann GE, Heizmann CW, Niggli E. Ca2+ signaling in mouse cardiomyocytes with ablated S100A1 protein. Gen Physiol Biophys 2009; 28: 371-383.
15. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Börries M et al. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci USA 2001; 98: 13889-13894.
16. Most P, Remppis A, Pleger ST, Löffler E, Ehlermann P, Bernotat J et al. Transgenic overexpression of the Ca2+ binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem 2003; 278: 33809-33817.
17. Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 2006; 114: 1258-1268.
18. Tsoporis JN, Marks A, Zimmer DB, McMahon C, Parker TG. The myocardial protein S100A1 plays a role in the maintenance of normal gene expression in the adult heart. Mol Cell Biochem 2003; 242: 27-33.
19. Völkers M, Loughrey CM, Macquaide N, Remppis A, DeGeorge Jr BR, Wegner FV et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 2007; 41: 135-143.
20. Remppis A, Greten T, Schafer BW, Hunziker P, Erne P, Katus HA et al. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta 1996; 1313: 253-257.
21. Brinks H, Rohde D, Völkers M, Qiu G, Pleger ST, Herzog N et al. S100A1 geneticallytargeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 2011; 58: 966-973.
22. Jessup M, Greenberg B, Mancini D, Cappola TP, Pauly DF, Greenberg B et al. CUPID-a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) in patients with advanced heart failure. Circulation 2011; 124: 304-313.
23. Tang T, Gao MH, Hammond HK. Prospects for gene transfer for clinical heart failure. Gene Ther 2012; 19: 606-612.
24. Dybkova N, Sedej S, Napolitano C, Neef S, Rokita AG, Hünlich M et al. Overexpression of CaMKIIdc in RyR2R4496C+/- knock-in mice leads to altered intracellular Ca2+ handling and increased mortality. J Am Coll Cardiol 2011; 57: 469-479.
25. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999; 96: 7059-7064.
26. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation 2004; 109: 1154-1160.
27. Pott C, Muszynski A, Ruhe M, Bögeholz N, Schulte JS, Milberg P et al. Proarrhythmia in a non-failing murine model of cardiac-specific Na+/Ca2+ exchanger overexpression: whole heart and cellular mechanisms. Basic Res Cardiol 2012; 107: 247.
28. Wittköpper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsöld B et al. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest 2010; 120: 617-626.
29. Maurice JP, Hata JA, Shah AS, White DC, McDonald PH, Dolber PC et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 1999; 104: 21-29.
30. Pleger ST, Remppis A, Heidt B, Völkers M, Chuprun JK, Kuhn M et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther 2005; 12: 1120-1129.
31. Chen Y, Escoubet B, Prunier F, Amour J, Simonides WS, Vivien B et al. Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmia. Circulation 2004; 109: 1898-1903.
32. Dixon JA, Spinale FG. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail 2009; 2: 262-271.
33. Hove-Madsen L, Bers DM. Sarcoplasmic reticulum Ca2+ uptake and thapsigargin sensitivity in permeabilized rabbit and rat ventricular myocytes. Circ Res 1993; 73: 820-828.
34. James J, Zhang Y, Wright K, Witt S, Glascock E, Osinska H et al. Transgenic rabbits expressing mutant essential light chain do not develop hypertrophic cardiomyopathy. J Mol Cell Cardiol 2002; 34: 873-882.
35. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007; 115: 2506-2515.
36. Most P, Pleger ST, Völkers M, Heidt B, Boerries M, Weichenhan D et al. Cardiac adenoviral S100A1 gene transfer rescues failing myocardium. J Clin Invest 2004; 114: 1550-1563.
37. Most P, Remppis A, Weber C, Bernotat J, Ehlermann P, Pleger ST et al. The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibers. J Biol Chem 2003; 18: 26356-26364.
38. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882-1890.
39. Buxton AE, Lee KL, DiCarlo L, Gold MR, Greer JS, Prystowsky N et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter unsustained tachycardia trial investigators. N Engl J Med 2000; 342: 1937-1945.